Table 3.
Bivariate analysis of the variables of interest according to the presence of short-term adverse effects in adults over 40 years of age who came to be vaccinated with the fourth dose against COVID-19 in Trujillo, Peru (N = 411).
| Variables | Presence of Adverse Effects | p-Value | |
|---|---|---|---|
| No | Yes | ||
| N = 54 (13.1%) | N = 357 (86.7%) | ||
| Sex | 0.043 | ||
| Female | 20 (9.8) | 185 (91.2) | |
| Male | 34 (16.5) | 172 (83.5) | |
| Age | <0.001 | ||
| <60 | 20 (8.1) | 227 (91.9) | |
| ≥60 | 34 (20.7) | 130 (79.3) | |
| BMI | 0.858 | ||
| Normal weight | 12 (12.1) | 87 (87.9) | |
| Overweight | 25 (12.8) | 170 (87.2) | |
| Obese | 17 (14.5) | 100 (85.5) | |
| Comorbidities | 0.368 | ||
| No | 47 (13.8) | 293 (86.2) | |
| Yes | 7 (9.9) | 64 (90.1) | |
| History of COVID-19 infection | 0.229 | ||
| No | 41 (14.5) | 242 (85.5) | |
| Yes | 13 (10.1) | 115 (89.9) | |
| vaccination scheme | 0.026 | ||
| Homologous | 44 (15.7) | 237 (84.3) | |
| Heterologous | 10 (7.7) | 120 (92.3) | |
| Last vaccine | |||
| mRNA-1273 (Moderna) | 45 (11.9) | 334 (88.1) | 0.009 |
| BNT162b2 (Pfizer-BioNtech) | 9 (28.1) | 23 (71.9) | |
| Simultaneous vaccination against influenza | 0.112 | ||
| No | 49 (14.3) | 293 (85.7) | |
| Yes | 5 (7.2) | 64 (92.8) | |
| Previous BBIBP-CorV | 0.048 | ||
| No | 46 (15.1) | 259 (84.9) | |
| Yes | 8 (7.6) | 98 (92.4) | |
BMI: Body Mass Index. p-Value obtained with chi-square test.